Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1140680 (ovarian cancer)
 28,141 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

CA-125 is a high-molecular-weight glycoprotein that is expressed on the cell surface of some derivatives of embryonic coelomic epithelium. Based on results of an immunoradiometric assay developed to detect CA-125 in peripheral blood, 82% of patients with ovarian cancer and less than 1% of apparently healthy controls have elevated peripheral blood levels of CA-125. Because endometriotic lesions are likely to be derivatives of embryonic coelomic epithelium, the authors investigated serum CA-125 levels in patients with endometriosis. Preoperative serum CA-125 concentrations were measured in 147 patients undergoing diagnostic laparoscopy or laparotomy. Serum CA-125 concentrations were elevated in patients with stage III or IV endometriosis, compared with controls with negative diagnostic laparoscopies (66.5 +/- 14.5 versus 8.20 +/- 0.59 U/ml, mean +/- standard error of the mean; P less than 0.001). Fifty-four percent of patients with stage III or IV endometriosis and 0% of the controls had CA-125 levels greater than 35 U/ml. Occasional patients with stage II endometriosis (13%), leiomyomata uteri (14%), and chronic pelvic inflammatory disease (5%) also had serum CA-125 concentrations greater than 35 U/ml. Immunocytochemical techniques demonstrated the presence of CA-125 on the cell surface of endometriotic lesions.
 ...
PMID:Elevated serum concentrations of CA-125 in patients with advanced endometriosis. 345 9

Murine IgG1 monoclonal antibody (MoAb) B72.3, reactive with a high molecular weight glycoprotein complex [designated tumor-associated glycoprotein-72 (TAG-72)] was shown, with the use of the avidin-biotin-complex-immunoperoxidase technique and surgically resected tissues, to be reactive with a variety of histologic tumor types. TAG-72 is expressed in at least 5% (and up to 100%) of the malignant epithelial cells in 77% (n = 52) of human primary cancers and 71% (n = 31) of metastatic ovarian cancers of the common "epithelia" histologic category. Of these, several histologic types, including serous and mucinous cystadenocarcinomas, undifferentiated carcinomas, and less common types of ovarian carcinoma, were all shown to express TAG-72. In contrast, normal ovarian tissues and 26 of 27 benign ovarian tumors of various histologic types failed to express similar levels of TAG-72. Of interest is the 1 benign tumor that demonstrated unusual glandular complexity, as well as 3 tumors designated as borderline malignancy, that contained elevated TAG-72 expression. MoAb B72.3 also was used successfully to detect ovarian carcinoma cells in 28 cytologic preparations of human serous effusions and peritoneal washings. The reactivity of MoAb B72.3 was shown to be distinct from that of MoAb OC125 and an anti-CEA MoAb B1.1. The potential applications of MoAb B72.3 in the study of human ovarian cancer cell populations, as well as in several aspects of the management of human ovarian cancer, are discussed.
 ...
PMID:Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. 352 78

We have previously described the monoclonal antibody (MAb) DF3, prepared against a human breast carcinoma. MAb DF3 reacts with a high molecular weight glycoprotein detectable in human breast carcinomas and in human milk. Previous studies have demonstrated that DF3 antigen levels are elevated in the plasma of patients with breast and ovarian cancer. The present study has further examined the reactivity of MAb DF3 with human ovarian carcinomas. Immunoperoxidase staining demonstrated reactivity of MAb DF3 with 95% of benign, borderline, and malignant tumors (serous, mucinous, and endometrioid) of the ovary. Furthermore, malignant tumors contained cytoplasmic DF3 antigen while benign tumors expressed the antigen only on apical surfaces. Western blot analyses demonstrated that the MAb DF3 reactive ovarian antigen (DF3-O) was a glycoprotein with a heterogenous molecular weight ranging between 300,000 and 450,000. This antigen was detectable by immunofluorescence on the cell surface of five of six cultured human ovarian carcinoma cell lines. The extent of cell surface reactivity with MAb DF3 was equivalent to or greater than that obtained with MAb OC125, an antibody generated against coelomic epithelium and developmental amnion. Furthermore, uptake of 125I-labeled MAb DF3 by human ovarian carcinoma xenografts in athymic mice was 5.4- and 6.2-fold higher than the respective uptake noted in liver and control tumor (P = 0.031). These findings suggest that DF3-O antigen is similar if not identical to the antigen detected in human breast carcinomas by MAb DF3. Thus, MAb DF3 may be a useful reagent in immunodiagnostic evaluation of patients with ovarian cancer.
 ...
PMID:Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. 353 Apr 35

NB/70K is a glycoprotein extracted from human ovarian cancer tissue. It was measurable postoperatively in the plasma of 89% of 127 women with epithelial cancer of the ovary; 60% of these women had levels in excess of 11 kU/mL compared with 5% of control subjects. The level of NB/70K correlated with FIGO stage and amount of residual tumor, but not with pathology subtype or tumor differentiation. Elevated NB/70K plasma levels also were found in patients with benign gynecologic neoplasms and a variety of systemic carcinomas, and modest elevation was observed in association with hepatic and renal decompensation. The highest levels, found preoperatively in women with ovarian cancer, decreased after tumor resection. These preliminary data indicate that the NB/70K assay has high sensitivity in epithelial ovarian cancer, and plasma levels appear to correlate with tumor volume.
 ...
PMID:Clinical correlations of ovarian cancer antigen NB/70K: a preliminary report. 385 94

Monoclonal IgG1 antibodies 2C8 and 2F7, derived by immunization of mice with a glycoprotein-enriched fraction of human ovarian adenocarcinoma, recognized a 60 kD glycoprotein in the ovarian tumor but not in normal ovary. Survey of other normal adult tissues by an indirect solid-phase radioimmunoassay (RIA) revealed the presence of the antigen in trace amounts in various normal organs such as small intestine, liver colon and urinary bladder, except in lung where its concentration was as high as in tumors. Among fetal tissues tested, intestine and placenta had the highest activities. By RIA, about 50% of ovarian and colonic tumors had elevated levels of the antigen. All ovarian cyst fluids, both benign as well as malignant, also contained a high level of the antigen. Immunodepletion studies indicated that the antigen was distinct from carcinoembryonic antigen and the ovarian cancer antigens described in our laboratory with other monoclonal antibodies. The antigen bound to Con A-Sepharose and was eluted with 2% alpha-D-mannoside, was soluble in 0.6 M perchloric acid and stable at 100 degrees C for 30 min. The antigenic activity in isolated plasma membrane enriched fractions of ovarian adenocarcinomas was sensitive to trypsin, chymotrypsin or protease treatment but unaffected by neuraminidase, beta-galactosidase, periodate or methanol treatment. By immunoperoxidase staining, the antigen was localized in a variety of human tumors showing widespread distribution.
 ...
PMID:Production and characterization of monoclonal antibody to a 60-kD glycoprotein in ovarian carcinoma. 389 88

Determinations of pregnancy-associated alpha-glycoprotein and immunosuppressive acidic protein in sera of patients have improved a detection rate of ovarian cancer in the early stage. In the clinical treatment of ovarian cancer, we employed the regimen based on results of experimental chemotherapy using heterotransplanted human tumors of the ovary. A regimen of cis-platinum, adriamycin and 5-fluorouracil combination in epithelial tumors and a regimen of cis-platinum, vinblastine and bleomycin combination in germ cell tumors may be recommended for treatment of ovarian cancer.
 ...
PMID:[Early diagnosis and effective treatment of ovarian cancer]. 619 76

A plasma membrane ectoenzyme in mammalian cells, 5'-nucleotidase, was evaluated as a marker for ovarian carcinoma. Activities of this enzyme were determined in homogenates from normal (N = 17) and malignant ovaries (N = 17), as well as in the sera from control women (N = 35), ovarian cancer patients with active disease (N = 24), and those in clinical remission (N = 9). A significant reduction of the activity of 5'-nucleotidase was observed in tumor homogenates compared with homogenates from normal ovaries. Levels of this enzyme in the sera of ovarian cancer patients were higher than in control women, suggesting the possibility of shedding of this enzyme from the tumor cell surface to the systemic circulation of the host. The diagnostic value of serum 5'-necleotidase levels was compared with another enzyme marker for ovarian carcinoma, viz. serum glycoprotein:galactosyltransferase. The upper limit of normal was set at 2 SD higher than the normal mean. Elevation of serum 5'-nucleotidase was observed in 12/24 (50%) patients with active disease, and 1/9 (11%) patients with clinical remission. In contrast, serum glycoprotein:galactosyltransferase was elevated in all the serum samples from patients with active disease and in none of those with clinical remission. There was some correlation between the serum levels of 5'-nucleotidase and those of glycoprotein:galactosyltransferase (0.01 less than P less than 0.05). Elevation of 5'-nucleotidase in the serum of these patients was not due to liver metastasis. Serum 5'-nucleotidase levels seem to correlate with disease status in some ovarian carcinoma patients, but in general it is inferior to serum glycoprotein:galactosyltransferase as a tumor marker.
 ...
PMID:Evaluation of 5'-nucleotidase as an enzyme marker in ovarian carcinoma. 626 38

alpha 1-acid glycoprotein (alpha 1AG) in the blood of gynecologic malignancy was measured by the S.R.I.D. method and analyzed by isoelectrofocusing. The usefulness of these methods for diagnosis and prognosis was examined. A. Quantitative analysis In normal healthy women alpha 1AG was measured (62.2 +/- 2.7 mg/dl) and did not increase before operation in benign gynecologic tumor. In cervical cancer, according to the development of cancer, a quantitative increase was apparent. Upon estimation, a significant difference from healthy women was observed at T1 but not T0. Two weeks after operation a quantitative increase was observed after which there was a gradual decrease but one year later not down close to the value before operation even in patients with good prognosis. In recurrent patients there was a marked increase. In ovarian cancer stage III, alpha 1AG markedly increased to 144.9 +/- 36.6 mg/dl before the operation, being a higher value. B. Isoelectrofocusing analysis Upon isoelectrofocusing, 9 bands were observed between pH3.1 and pH3.5. In normal healthy women I and IX bands were not recognized. In cervical cancer an increase in ratio groups I and II and groups VIII and IX and a decrease in ratio group (IV, V, VI) were seen according to development of the cancer. Ovarian cancer showed the same course as cervical cancer. The measurement and the isoelectrofocusing analysis of alpha 1AG were useful for diagnosis of gynecologic malignancy and its prognosis, and these methods are especially useful in case of ovarian cancer.
 ...
PMID:[Isoelectroforetic analysis of alpha 1-acid glycoprotein (alpha 1-AG) in gynecological malignancy]. 630 11

This chapter summarizes the various epithelial ovarian cancer markers which have been termed cystadenocarcinoma 'antigens'. Virtually every reported antigen has been demonstrated by raising antibodies to tumour extracts injected into heterologous animals. As yet, despite numerous attempts, no heterologous antiserum has been demonstrated to have the requisite sensitivity and specificity for the immunodiagnosis of early ovarian cancer. However, some of the antigen markers may prove useful in monitoring the response to therapy. Hybridoma-generated monoclonal antibodies could prove to be the means by which the immunodiagnosis of early ovarian cancer will be achieved. That the abnormal antigens reflect altered glycoprotein metabolism is suggested by the findings of elevated serum galactosyltransferase, which in itself is a good ovarian cancer tumour marker, and a genetic serum deficiency of alpha-L-fucosidase, which appears to identify a high risk population for the development of ovarian cancer.
 ...
PMID:Tumour-associated antigens for cystadenocarcinoma of the ovary. 641 13

A study of possible biochemical markers of tumor recurrence and progression was made in 93 patients with ovarian cancer followed longitudinally for up to 2 years during treatment by moderate or aggressive chemotherapy regimens. A panel of potential indicators was tested; the combination of serum albumin, C-reactive protein, alpha 1-acid glycoprotein, and phosphohexose isomerase levels was found to provide information that is useful as an adjunct to the clinical assessment of patients with advanced disease. However, the system could not detect a small tumor burden. The level of beta 2-microglobulin may have value in those patients whose tumor is associated with an increase of this analyte (77%), but it would appear to reflect a large tumor mass. Serum CEA, carcino-placental alkaline phosphatase, transferrin, and prealbumin were not found to be helpful.
 ...
PMID:Biochemical aids in the monitoring of patients with ovarian cancer. 662 22


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>